Scarica l'app Stockscreener
0.5955
2.70%
-0.0165
Pre-mercato:
.60
0.0045
+0.76%
Precedente Chiudi:
$0.612
Aprire:
$0.6015
Volume 24 ore:
551.45K
Relative Volume:
0.57
Capitalizzazione di mercato:
$31.79M
Reddito:
-
Utile/perdita netta:
$-151.16M
Rapporto P/E:
-0.2005
EPS:
-2.97
Flusso di cassa netto:
$-130.08M
1 W Prestazione:
-12.37%
1M Prestazione:
-45.86%
6M Prestazione:
-67.46%
1 anno Prestazione:
-94.44%
Intervallo 1D:
$0.571
$0.6298
Intervallo di 1 settimana:
$0.571
$0.72
Portata 52W:
$0.571
$17.82
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Nome
Alx Oncology Holdings Inc
Settore
Industria
Telefono
650-466-7125
Indirizzo
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Confronta ALXO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
0.5955 | 31.79M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2024-03-08 | Downgrade | Stifel | Buy → Hold |
| 2023-12-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-12-22 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-06 | Iniziato | UBS | Buy |
| 2021-02-10 | Iniziato | H.C. Wainwright | Buy |
| 2020-08-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-08-11 | Iniziato | Credit Suisse | Outperform |
| 2020-08-11 | Iniziato | Jefferies | Buy |
| 2020-08-11 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Alx Oncology Holdings Inc Borsa (ALXO) Ultime notizie
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
ALXO stock touches 52-week low at $0.65 amid market challenges - Investing.com
Cantor Fitzgerald Raises Earnings Estimates for ALX Oncology - Defense World
ALXO stock plunges to 52-week low of $0.73 amid market challenges - Investing.com Australia
ALXO stock plunges to 52-week low of $0.73 amid market challenges By Investing.com - Investing.com South Africa
ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday - MSN
ALXO stock touches 52-week low at $0.89 amid market challenges - Investing.com Australia
ALXO stock touches 52-week low at $0.89 amid market challenges By Investing.com - Investing.com South Africa
Insider Buying: Rekha Hemrajani Acquires 30,000 Shares of ALX On - GuruFocus.com
ALX Oncology Holdings: Balancing Growth Potential and Uncertainty with a Hold Rating - TipRanks
Stifel Nicolaus Lowers ALX Oncology (NASDAQ:ALXO) Price Target to $1.50 - Defense World
ALX Oncology (NASDAQ:ALXO) Earns “Buy” Rating from HC Wainwright - Defense World
Why the Global Cancer Market Could Surpass $900 Billion-And the Stocks Leading the Charge - The Malaysian Reserve
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - PR Newswire
Sun Valley buying at Canagold Resources (CCM) - The Globe and Mail
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Jefferies Financial Group Upgrades ALX Oncology (NASDAQ:ALXO) to “Buy” - Defense World
Stifel cuts ALX Oncology stock target to $1.50, maintains hold By Investing.com - Investing.com Canada
Promising Developments in ALX Oncology’s Clinical Pipeline Justify Buy Rating - TipRanks
Jefferies raises ALX Oncology stock to buy, target to $3 By Investing.com - Investing.com South Africa
ALX Oncology Reports 2024 Financial Results and Updates - TipRanks
Micro-, Small-Cap Firms Dominate Market Rally - Insider Monkey
Alx Oncology Holdings Inc Files For Mixed Shelf Of Up To $364.1 Million -March 06, 2025 at 05:35 pm EST - Marketscreener.com
ALX Oncology Holdings Inc (ALXO) Q4 2024 Earnings: EPS of -$0.55 Beats Estimate, Revenue Matches Forecast - GuruFocus.com
ALX Oncology Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
ALX Oncology jumps as Jefferies upgrades on upside potential - MSN
ALX Oncology stock jumps as Jefferies upgrades(ALXO:NASDAQ) - Seeking Alpha
This Zscaler Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga India
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - Barchart
ALX Oncology Cuts 30% Workforce, Eliminates President And CSO Role Amid Pipeline Prioritization - Nasdaq
Jefferies Upgrades ALX Oncology to Buy From Hold, Adjusts Price Target to $3 From $2 - Marketscreener.com
Jefferies Upgrades ALX Oncology Holdings (ALXO) - Nasdaq
ALX Oncology Holdings: Undervalued with Promising Catalysts and Growth Opportunities - TipRanks
Jefferies raises ALX Oncology stock to buy, target to $3 - Investing.com
ALX Oncology announces workforce reduction and officer departure By Investing.com - Investing.com Australia
ALX Oncology announces workforce reduction and officer departure - Investing.com India
ALX Oncology Announces Workforce Reduction and Leadership Change - TipRanks
ALX Oncology to Cut Workforce by 30% to Support New Clinical Initiatives -March 05, 2025 at 11:04 am EST - Marketscreener.com
ALX Oncology Highlights Focused Evorpacept Development - GlobeNewswire
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event - Yahoo Finance
ALXO stock plunges to 52-week low, touches $0.96 By Investing.com - Investing.com South Africa
ALXO stock plunges to 52-week low, touches $0.96 - Investing.com
ALX Oncology (ALXO) to Release Earnings on Thursday - MarketBeat
When Will ALX Oncology Share Its 2024 Financial Performance? Key Date for Biotech Investors - StockTitan
Alx Oncology Holdings Inc Azioni (ALXO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):